Wedbush Starts Tscan Therapeutics Inc (TCRX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures muted as oil holds near April highs ahead of Fed decision
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts TCRX Hot Sheet
Price: $0.19 --0%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 14
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 14
Join SI Premium – FREE
Wedbush analyst David Nierengarten initiates coverage on Tscan Therapeutics Inc (NASDAQ: TCRX) with a Outperform rating and a price target of $8.00.
For an analyst ratings summary and ratings history on Tscan Therapeutics Inc click here. For more ratings news on Tscan Therapeutics Inc click here.
Shares of Tscan Therapeutics Inc closed at $2.83 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Roth/MKM Starts Dianthus Therapeutics (DNTH) at Buy
- Oppenheimer Starts MSC Income Fund Inc (MSIF) at Outperform
- Piper Sandler Assumes PBF Energy (PBF) at Neutral
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
